Hematopoietic stem cell (HSC) transplantation is the most effective therapeutic modality for certain malignant and non-malignant diseases. Although umbilical cord blood can be a source of HSCs, the harvest from a single cord is insufficient for transplantation. Protocols have been developed to overcome this problem, but in vivo expansion of transplanted HSCs would be most desirable. Serotonin is a monoamine neurotransmitter that can increase the ex vivo expansion of both HSCs and bone marrow stromal cells (BMSCs). Selective serotonin reuptake inhibitors (SSRIs) increase the free serotonin concentration by binding to the serotonin transporter (SERT), thereby preventing reuptake by pre-synaptic cells. Studies have shown that SSRIs also have immunosuppressive effects. We hypothesized that the immunosuppressive effects of SSRIs may be due to the expansion of BMSCs, which can result in a decrease in the incidence of graft versus host disease (GVHD). Finally SSRIs may promote efficacy of transplantation by increasing the in vivo expansion of HSCs and decreasing GVHD incidence.
Introduction
Hematopoietic stem cells (HSCs) are stem cells that have the potential to develop into blood and immune cells. Especially, HSCs are defined by their ability to self-renew and produce cells able to differentiate into any blood cell type, although only small numbers divide and differentiate to a mature lineage. 1, 2 These properties render HSCs attractive for use in stem cell therapies. 3 Transplantation of HSCs is the most effective modality for treating malignant and non-malignant diseases including leukemias and lymphomas, aplastic anemia, and hemoglobinopathies; genetic disorders such as lysosomal storage disease 4, 5 ; and immunodeficiencies such as human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). 6 The most common sources of HSCs for transplantation are bone marrow and mobilized peripheral blood. 7 Major factors limiting the success of transplantation from these sources are graftversus-host disease (GVHD) 8, 9 and engraftment failure. 10 Since 1988, umbilical cord blood has increasingly become an alternative source of HSCs for transplantation, 11 due to easy availability, lower risk of viral infection, and reduced GVHD. 12 The number of HSCs in umbilical cord blood is low, but a population adequate for transplantation may be gained via ex vivo expansion. 12 Most methods of ex vivo expansion, however, are not able to maintain stem cell properties and therefore are not appropriate for clinical application. Most desirable would be a new method that can induce the in vivo expansion of HSCs.
Small-molecule compounds (SMCs) are a relatively new tool for the expansion of HSCs, 13 although these natural chemical products have been used in molecular biology and pharmacological treatments for many years. It has been shown that SMCs are able to modulate the signaling pathways of HSCs. 14 One of these SMCs is serotonin (or 5-hydroxytryptamine, 5-HT), 15 a monoamine neurotransmitter that is often produced in Enterochromaffin (EC) cells of the gut and brain, and stored in platelets and mast cells. 16, 17 Antidepressant drugs known as selective serotonin reuptake inhibitors (SSRIs) prevent the uptake of serotonin by SERT (serotonin reuptake transporter). This results in enhanced serotonin signaling. 18, 19 SSRIs are used to treat many diseases, including major depression and anxiety disorders (e.g., obsessive-compulsive disorder and panic disorder). Relative to other antidepressants, they cause fewer undesirable side effects. Paroxetine, citalopram, fluvoxamine, sertraline and fluoxetine are examples of SSRIs. [20] [21] [22] SSRI treatments have been associated with changes in the proliferation, cytokine secretion, and viability of peripheral blood lymphocytes. 19 Generally, SSRIs appear to inhibit the proliferation of T lymphocytes, with the exception of fluoxetine, whose stimulatory or inhibitory effects are dependent on the concentration of mitogen (concavalin A) and degree of lymphocyte activation in vitro. 23, 24 Serotonin has been identified as an important factor in the activation of T lymphocytes. Evidence-based conclusions are that serotonin receptors are not responsible for the mitogenic effects of serotonin on T lymphocytes, but rather SERT is responsible for these effects via the uptake of serotonin; internalization of serotonin through SERT leads to the proliferation of these cells. Therefore, the anti-proliferative effects of SSRIs can be explained by the inhibition of serotonin uptake. 19 SSRIs are able to affect other parameters related to lymphocytes, such as cytokine secretion. Taler et al. 25 showed that, ex vivo, a higher concentration of the SSRIs paroxetine and sertraline Anbarlou A. et al: Selective serotonin reuptake inhibitors (10 µM) was associated with inhibition of T cell proliferation and reduced secretion of tumor necrosis factor (TNF)-α. These effects were related to the inhibition of gene expression by SSRIs, genes that are involved in the proliferation and inflammatory responses of lymphocytes. [25] [26] [27] In addition, SSRIs induce apoptosis in lymphocytes. All SSRIs used in clinical practice (paroxetine, citalopram, fluvoxamine, sertraline and fluoxetine) had this apoptotic effect. Moreover, serotonin induces apoptosis in Burkitt's lymphoma cells. Therefore, the pro-apoptotic function of SSRIs may be related to increased extracellular serotonin. 19 The above discussion highlights that most researchers have reported immunosuppressive effects associated with SSRIs, effects that include lymphocyte proliferation and secretion of pro-inflammatory cytokines. Fluoxetine was shown to exert both immunosuppressive and immunomodulatory effects depending on the used concentration, but other SSRIs such as sertraline and paroxetine were associated with only immunosuppressive effects.
Fluoxetine (20 mg/kg) was able to reduce the clinical symptoms of acute GVHD after HSC transplantation. In the peripheral blood of mice treated with fluoxetine, a low percentage of alloreactive T-cells were detected. This indicates that fluoxetine can reduce the proliferation of alloreactive T-cells, increase the apoptosis of these cells, or both. In addition, fluoxetine increased the survival of mice by at least 6 months post-transplantation. 28 
Hypothesis
By increasing the amounts of serotonin in bone marrow, SSRIs may improve the efficacy of HSC transplantation (Fig. 1) . Most studies concerning SSRIs have focused on the effects of sertraline and fluoxetine. Because the effects of fluoxetine on lymphocytes are variable under different conditions, we suggest sertraline, as its effect is solely immunosuppressive. The routine starting dosage of sertraline as an antidepressant is 50 mg/day, and the maximum is 200 mg/day, 29,30 but higher doses are probably required for immunosuppression. 19 The normal concentration of serotonin in plasma is 0.62±0.11 µg/L. 31 Future studies must focus on the dosage of sertraline that will generate the optimum concentration of plasma serotonin for in vivo expansion of HSCs.
Evaluation of hypothesis
In addition to bone and hematopoietic cells, nerve cells are also within the microenvironment of the bone marrow, and interactions among these cells regulate the fate of stem cells in vivo. 15 The following evidence suggests that these complex interactions may be through the serotonin neurotransmitter. Firstly, serotonin can stimulate megakaryopoiesis via the 5-HT 2 receptor. 32 In the early stages of megakaryocytopoiesis, serotonin regulates proliferation and survival of megakaryoblasts through its anti-apoptotic effects. 32, 33 SERT in also found on platelets, enabling storage of serotonin in the blood. 34 About 90% of the serotonin in blood is stored in dense granules of platelets. Since the expression of SERT on megakaryocytic lineage has been demonstrated, 34 we can hypothesize that SERT is also expressed in megakaryoblasts. Yang et al. 32 observed reduced levels of caspase-3 in megakaryoblastic cells (M-07e) treated with serotonin. The anti-apoptotic effects of serotonin are similar to that of thrombopoietin, a known cytokine in hematopoiesis and megakaryocytopoiesis. 32 Kirouac et al. 15 also showed that serotonin is produced endogenously by hematopoietic cells. Thus, perhaps megakaryocytes are involved in this process. As we know, HSC expansion is associated with the development of megakaryocytes, 15 and serotonin secreted from megakaryocytes promotes stem cell self-renewal. 15, 35 That the fate of stem cells in vivo may be ultimately regulated through the serotonin neurotransmitter is further supported by reports that serotonin was associated with increased ex vivo expansion of CD34 + HSCs in mice 32, 36 ; Yang et al. 32 reported that serotonin expanded CD34 + cells by 12.2 ± 1.79-fold ex vivo. The expansion not only led to cell proliferation but also to increased levels of early progenitors and the density of multilineage colony-forming units. Serotonin enhanced the proliferation of HSCs in bone marrow via activation of the 5-HT 2 receptor. 36 In parallel with previous studies, Spiegel et al. 37 also showed that serotonin increased HSC proliferation and engraftment in vivo. Moreover, PNU 22394 (a 5-HT 2 agonist) led to reduced levels of erythroid precursors in bone marrow through 5-HT 2A and 5-HT 2B receptors. This proliferative effect on erythroid precursors is similar to that exerted by serotonin. 33 Finally, further evidence of the role of serotonin neurotransmitters is that serotonin was found to stimulate the formation of bone marrow stromal cells (BMSCs) from colony-forming unit fibroblasts. 32 BMSCs have immunoregulatory properties and they can affect the development, maturation, and function of immune effector cells such as alloreactive T-cell responses. 17 
Discussion and conclusions
There are several sources of serotonin in the body. Among them, infiltrating neurons in bone marrow and other tissues may secrete serotonin and other ligands that can affect the expansion of HSCs. 35 We consider that human consumption of SSRIs after infusion of CD34 + HSCs may be beneficial from multiple aspects. Anbarlou A. et al: Selective serotonin reuptake inhibitors These drugs can increase the accessibility of serotonin to HSCs by several pathways; one of which is blockage of SERT in the nerve terminals of infiltrating neurons to the bone marrow microenvironment and megakaryoblast. Reuptake of serotonin is prevented by inhibition of SERT, and therefore serotonin concentrations increase in the microenvironment of the bone marrow.
There is also some evidence that megakaryoblasts are able to synthesize serotonin. 15, 35 Our hypothesis is that serotonin cannot enter megakaryoblasts because of SERT blockage. It seems likely that this results in elevated levels of serotonin in the bone marrow, by increasing serotonin synthesis via megakaryoblasts (compensating for serotonin deficiency). Finally, this will lead to the expansion of CD34 + HSCs and early progenitors, in vivo.
Serotonin also can increase expansion of BMSCs. 32 These cells have immunoregulatory properties and can decrease GVHD symptoms. To take advantage of this property, co-infusion of mesenchymal stem cells with CD34 + HSCs was recently reported as a novel protocol in HSC transplantation. [38] [39] [40] On the other hand, some studies have shown that SSRIs have immunosuppressive effects, and we hypothesized that this may be due to increased serotonin in the bone marrow microenvironment that leads to an increase in the expansion of BMSCs. Therefore, the observed immunosuppressive effects may be the result of expansion of BMSCs that lead to a decrease in GVHD symptoms. Hirota et al. 17 demonstrated that serotonin (10 µM) was able induce rat BMSC differentiation into smooth muscle-like cells in vitro. Moreover, SSRIs (except citalopram) have been shown to have negative effects on human osteoclasts and osteoblasts. 41 Thus the possible side effects of SSRIs should be considered.
Altogether we conclude that SSRIs may promote the efficacy of HSC transplantation by increasing the in vivo expansion of HSCs and decreasing the incidence of GVHD.
